Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,232 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,064
- Phase 1822
- Phase 1/Phase 2446
- Phase 3425
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis344
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia98
- Autoimmune Diseases81
- Follicular Lymphoma73
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)75
- Assistance Publique - Hôpitaux de Paris69
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center62
- AstraZeneca57
- Mayo Clinic47
- City of Hope Medical Center46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama180
- Florida142
- Arizona140
- New York122
- Massachusetts120
- Texas118
- Illinois82
- Colorado77
Recruiting studies6,232 total
- NCT07525375RecruitingPhase 2
Lung Function Study of Inhaled Glycopyrronium With BFF in Children With Asthma
This study tests whether adding a medication called glycopyrronium to a common asthma inhaler (BFF) helps children ages 4–12 breathe better. Researchers will measure lung function and compare two different doses of the added medication.
Bakersfield, CaliforniaAges 4–11 - NCT06383338RecruitingPhase 1
Metabolism Changes in Young People with Lymphoma
This study looks at how your body's metabolism (processing of food and medicine) changes after you start treatment for lymphoma. It uses two safe, commonly used drugs (omeprazole and dextromethorphan) to measure these changes.
Melbourne, VictoriaAges 6–25 - NCT05288790RecruitingPhase 2
Study how gut chemicals and alcohol affect heart risk in HIV
This Phase 2 study looks at how “microbiome metabolites” (chemicals from gut bacteria) and alcohol may affect heart and blood vessel risk in people living with HIV. If you qualify, you may be asked to follow a study plan to see how these factors change health markers related to cardiovascular disease.
Nashville, TennesseeAges 18–89 - NCT06931990RecruitingPhase 1/Phase 2
Testing a new tablet for eczema in Chinese adults
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT06393738RecruitingPhase 1
ARV-393 for relapsed or refractory non-Hodgkin lymphoma
This study tests a new oral medication (ARV-393) for people with certain types of non-Hodgkin lymphoma that have returned or not responded to previous treatments. The drug is designed to target a protein inside cancer cells to make them stop growing and die.
New Haven, ConnecticutAges 18 years+ - NCT07788456RecruitingPhase 4
Sequential combination therapy for newly diagnosed ITP in adults
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
TianjinAges 18–75 - NCT06846281RecruitingPhase 3
Remibrutinib for relapsing multiple sclerosis after switching from Ocrevus
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Scottsdale, ArizonaAges 40–70 - NCT05495035RecruitingPhase 1
Olverembatinib plus APG-2575 for children with resistant leukemia
This study tests a new combination of two oral drugs (olverembatinib and APG-2575) for children with a type of leukemia (Ph+ ALL) that has returned or stopped responding to standard treatments. The goal is to see if this combination is safe and effective.
Hefei, AnhuiAges 1–18 - NCT07786870Recruiting
Understanding airway proteins in asthma
This study examines a protein called TSLP that may play a role in asthma inflammation. By looking at different versions of TSLP in your airway samples, researchers hope to learn more about asthma and potentially guide future treatments.
Warsaw, WarsawAges 18 years+ - NCT04504955Recruiting
Atopic dermatitis patient registry for medication safety and results
This study is a real-world registry that collects information from adults with atopic dermatitis (eczema) to track how newly started treatments work and how safe they are over time. It may help researchers and doctors better understand medication effects in everyday care.
Waltham, MassachusettsAges 18 years+ - NCT06227026RecruitingPhase 1
CAR-T cell therapy for blood cancers that returned
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
Salt Lake City, UtahAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+ - NCT07788118RecruitingPhase 1/Phase 2
A new car-t therapy for relapsed large b-cell lymphoma
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hangzhou, ZhejiangAges 18–75 - NCT07787247Recruiting
Remote monitoring for myasthenia gravis patients
This study tests whether remote monitoring through smartphone apps can effectively track myasthenia gravis symptoms and help manage care from home, instead of frequent in-person visits.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07341191RecruitingPhase 2
Sonrotoclax and zanubrutinib before CAR-T for mantle cell lymphoma
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
Edmonton, AlbertaAges 18 years+ - NCT06920004RecruitingPhase 3
Testing empasiprubart vs IVIg for chronic CIDP
This study tests an investigational drug called empasiprubart against standard IVIg in adults with CIDP. The goal is to see if it is safer and more effective for people who still have symptoms despite IVIg therapy.
Birmingham, AlabamaAges 18 years+ - NCT06962800RecruitingPhase 3
Study of felzartamab for adults with primary membranous nephropathy
This study tests whether felzartamab, given as an infusion, can help treat primary membranous nephropathy (a kidney disease causing protein in the urine and swelling). It may reduce protein loss and improve kidney function compared to standard care alone.
Huntsville, AlabamaAges 18–80 - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Chicago, IllinoisAges 18–80 - NCT05494346Recruiting
Seawater nasal spray with essential oils for blocked nose
This trial tests whether a seawater nasal spray (with essential oils) is safe and works well for people ages 12+ who have sudden (acute) cold- or allergy-related nasal blockage. You may be able to join if you can use the spray as instructed and complete simple monitoring and questionnaires.
Blainville-sur-OrneAges 12 years+ - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Homewood, AlabamaAges 18 years+ - NCT07457580Recruiting
A real-world study of teplizumab for type 1 diabetes
This study looks at real-world outcomes in patients with type 1 diabetes who received teplizumab through managed access programs. It helps researchers understand how well the treatment works outside of a clinical trial setting.
LeuvenAges Any age - NCT07188285Enrolling by invitation
Immune system study for active autoimmune diseases
This study uses a blood test called mass spectrometry to look at the immune system in people with active autoimmune diseases. It aims to find patterns that could help doctors better understand and treat these conditions.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05776927RecruitingPhase 3
Testing a new inhaler for teens with asthma
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
Tarnów, PolandAges 12–17 - NCT06649201Recruiting
Study of vaginal health after stem cell transplant
This study looks at how stem cell transplants affect the vagina, especially if you develop a condition called graft-versus-host disease (GVHD). Researchers will examine the vagina and test its natural germs (microbiome) to better understand and possibly improve treatment.
Cleveland, OhioAges 18–70
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,232 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,656 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.